

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Raily Aesthetic Medicine International Holdings Limited

瑞麗醫美國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2135)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Board, the Group is expected to record a profit attributable to the shareholders of the parent of approximately RMB1 million for the six months ended 30 June 2022 as compared to the loss attributable to the shareholders of the parent of approximately RMB5 million for the six months ended 30 June 2021.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on a preliminary assessment of the unaudited management accounts of the Group for the six months ended 30 June 2022 and the information currently available to the Board:

- (i) the Group is expected to record a revenue of approximately RMB94 million for the six months ended 30 June 2022 as compared to approximately RMB91 million for the six months ended 30 June 2021; and
- (ii) the Group is expected to record a profit attributable to the shareholders of the parent of approximately RMB1 million for the six months ended 30 June 2022 as compared to the loss attributable to the shareholders of the parent of approximately RMB5 million for the six months ended 30 June 2021.

The Board considers that the expected turnaround in the results for the six months ended 30 June 2022 is mainly attributable to the following reasons:

- (i) the growth in the performance of aesthetic medical services segment;
- (ii) the decrease in promotion and marketing expenses; and
- (iii) the decrease in exchange loss.

The Company is still in the process of finalising the Group’s consolidated interim results for the six months ended 30 June 2022. The information contained in this announcement is only based on a preliminary assessment of the Group’s unaudited management accounts for the six months ended 30 June 2022 and the information currently available to the Board, which have not been reviewed or audited by the Company’s Auditors or reviewed by the audit committee of the Board and is subject to amendments and adjustments where necessary. Details of the financial information of the Group will be disclosed in the interim results announcement of the Company for the six months ended 30 June 2022 which is expected to be published by the end of August 2022 in accordance with the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Raily Aesthetic Medicine International Holdings Limited
FU Haishu
Chairman and Executive Director

Hangzhou, the PRC, 19 August 2022

As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; Ms. Fan Qirui as Non-executive Director; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.